



SAVE E3UU ENBER BOOKSAVE E100 SMi presents its 13th annual conference on...

# Clinical Trials in CNS

# Marriott Regents Park Hotel, London, UK

# 11 - 12 NOV 2014



#### **Conference Chairs:**

- Richard Wyse, Director of Research and Development, The Cure Parkinson's Trust
- Craig Ritchie, Clinical Senior Lecturer, Imperial College London

**Key Speakers:** 

- Tine Bryan Stensbøl, Divisional Director Discovery Pharmacology Research, Lundbeck
- Alan Palmer, Co-Founder and Director, MS **Therapeutics**
- Veronique Bragulat, Clinical Imaging Manager, GSK
- Sophie Dix, Senior Research Scientist, Neurodegenerative Diseases Drug Hunting Team, Eli Lilly
- David Willé, Applied Statistician, GSK
- Peter Joseph Jongen, Founding Director, MS4 **Research Institute**
- Ernst-Wilhelm Radue, CEO, MIAC AG
- Edwin Johnson, Director, Stockholm Brain Institute
- Shahid Zaman, Affiliated Lecturer, University of Cambridge

...and many more!

#### Why Attend This Event:

- Understand the recent failures in CNS development and how translation did not work
- Examine the multi-stakeholder approach to selfmanagement and multidisciplinary care in patients with MS
- **Discuss** the past, present and future of CNS medicines research
- Analyse novel biomarkers for the brain
- Review the collaboration between industry and academic partnering

PLUS AN INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOP Thursday 13th November 2014, Marriott Regents Park Hotel, London

#### Clinical Trials in CNS: The role of academic institutions as CROs

Workshop Leader: Professor Ernst-Wilhelm Radue, CEO, MIAC 8.30am - 12.30pm

# www.clinicaltrialscns.com

Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711 **ACADEMIC & GROUP DISCOUNTS AVAILABLE** 



# **Clinical Trials in CNS 2014**

## Day One I Tuesday 11th November 2014

#### 8.30 **Registration & Coffee**

9.00 **Chairman's Opening Remarks** Richard Wyse, Director of Research and Development, The Cure Parkinson's Trust

#### IMPROVING CLINICAL TRIAL OUTCOMES AND DESIGNS

#### 9.10 Analysis of brain MRI for diagnosis of MS

- MRI features represents neuropathology
- Cerebral atrophy in MS
- Data flow and data transfer
- Quality control
- Making diagnosis clinic MRI lesions
- Ernst-Wilhelm Radue, CEO, MIAC AG

#### 12.20 Networking Lunch

#### Patient recruitment and retention issues in CNS clinical trials 1.30

- Patient population insights that need to be considered in designing recruitment and retention programs for CNS trials
- Retaining the enrolled patient throughout the trials
- Recruitment and retention issues in patients with neurodegenerative disorders

#### **Speaker TBC**

#### **BIOMARKERS & CNS**

#### 2.10 The use of neuroimaging biomarkers in drug development

- Understanding the brain mechanism
- The role of CNS biomarkers
- Latest studies carried out and results

Mitul Mehta, Senior Lecturer, King's College London

#### 2.50 Afternoon Tea

- 3.20 Imaging multicentre clinical trials: Challenges and best practice specific to CNS
  - Overview of multicentre clinical trials in CNS
  - Challenges of imaging in multicentre trials
  - How to improve quality?
  - How to implement new techniques?

Veronique Bragulat, Clinical Imaging Manager, GSK

#### 4.00 Investigation of novel functional and metabolic MRI biomarkers for the preclinical assessment of taupathology in AD

- Preclinical biomarkers of taupathology in Alzheimer's disease
- Drug discovery
- Magnetic resonance imaging, metabolism and experimental therapeutics

Niall Colgan, Research Associate, UCL Centre for Advanced **Biomedical Imaging** 

4.40 Chairman's Closing Remarks and Close of Day One

#### Analysis of recent failures in CNS drug development and how translation did not deliver • Overview of the recent clinical trials in CNS

- Translational tools used
- Bridging the gap between pre-clinical and clinical CNS trials

Edwin Johnson, Director, Stockholm Brain Institute

#### 10.30 Morning Coffee

9.50

- 11.00 The multi-stakeholder approach to self-management and multidisciplinary care in patients with MS
  - The need to include all stakeholders in MS
  - MSmonitor as a solution to professional care and selfmanagement of MS
  - Recent additions and development to the web-based program
  - The opportunity to adapt the program to other neurodegenerative diseases?
  - How has this interactive tool impacted on the patient Peter Joseph Jongen, Founding Director, MS4 Research Institute

#### 11.40 CNS medicines research: Past, present and future

- The history of CNS medicines R&D
- The CNS medicines landscape today
- The future of CNS pharmacotherapy

Alan Palmer, Co-Founder and Director, MS Therapeutics

#### WHO SHOULD ATTEND THIS CONFERENCE:

You should attend this event if you are a Medical Director, Research Scientist, Fellow, Statistician, Senior Research Scientist, Director, Academic from within the Pharmaceutical or Healthcare industry with responsibilities in the following areas:

- CNS Clinical Discovery/Nervous System Research
- Clinical Trial Management and Operation
- CNS Therapeutics and Molecular Profiling
- Neurology/Neuroscience
- Pain Research/Management • Biomarkers and Imaging
- Pre-Clinical/Clinical R&D

- Clinical Pharmacology
- Patient Recruitment
- Translational Medicine
- Biostatistics and Modelling
- Emerging Targets/Lead Optimisation
- Genomics/Bioinformatics/Neuroinformatics

Want to know how you can get involved?

Interested in promoting your services to this market?

Contact Sarah Watson, SMi Marketing on +44 20 7827 6134, or email: swatson@smi-online.co.uk

Register online at: www.clinicaltrialscns.com • Alternatively fax y

# trialscns.com

# **Clinical Trials in CNS 2014**

Day Two I Wednesday 12th November 2014

- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks Craig Ritchie, Clinical Senior Lecturer, Imperial College London

#### LATEST DEVELOPMENTS AND STUDIES IN CNS RESEARCH

#### 9.10 The NEWMEDS project: New frontiers in Schizophrenia research

- Achievement of a public private partnership
- Have we progressed our understanding of Schizophrenia in the last 5 years
- Novel animal models of schizophrenia
- Opportunities for the future: developing novel drugs for schizophrenia. Where do we stand?
   Tine Bryan Stensbøl, Divisional Director Discovery

Pharmacology Research, Lundbeck

- 9.50 Incentives for research: facilitating industry and academic partnering
  - What are the challenges in CNS research and how can partnering help in drug discovery
  - Recent experiences from partnering and collaborationsFuture opportunities

Sophie Dix, Senior Research Scientist, Neurodegenerative Diseases Drug Hunting Team, Eli Lilly

#### 10.30 Morning Coffee

- 11.00 Do Alzheimer's and Parkinson's disease share common genetic risk?
  - Examining the genetic overlap between PD and AD
  - Data combined from various countries for genome-wide analysis
  - Results of the study

Valentina Escott-Price, Senior Lecturer, Institute of Psychological Medicine and Clinical Neurosciences

- 11.40 Proof of concept trials in Alzheimer's dementia: Novel approaches adapting to the needs
  - What was wrong with the old way of doing things
  - The definition of secondary prevention and meaning of Proof of Concept
  - Global consortia and their approach to the problem
  - Can we sustain a new 'machine' for phase 2 AD trials in Europe

Craig Ritchie, Clinical Senior Lecturer, Imperial College London

#### 12.20 Networking Lunch

#### 1.30 Latest developments in Parkinson's disease

- Developing new treatments to address motor and cognitive symptoms in Parkinson's Disease (PD)
- Challenges in carrying out clinical trials in PD
- How likely is it to translate current research in PD to other diseases of the CNS?

**Richard Wyse**, Director of Research and Development, **The Cure Parkinson's Trust** 

#### 2.10 Clinical studies in Alzheimer's disease in Down syndrome

- Understanding the mechanisms of AD in trisomy of chromosome 21
- The role of amyloid and mitochondrial dysfunction in dementia and people with Down's syndrome
- Latest results obtained from studies
   Shahid Zaman, Lecturer, University of Cambridge

shana zanan, zociolol, shiveishy of cambridge

I needed this conference to quickly boost my understanding of current clinical trial activity. This was a great success.

#### 2.50 Afternoon Tea

#### 3.20 The PharmaCog project

- The rationale behind the PharmaCog project
- The challenges for new drug development in Alzheimer's disease
- Project results achieved

David Willé, Applied Statistician, GSK

#### 4.00 Pre-clinical trials: New treatment targeting versatile protein in Parkinson's disease

- Activation of the Sigma-1 receptor as a defence mechanism
- Results from the pre-clinical studies
- Future clinical trials on Alzheimer's patients?
- Veronica Francardo, Assistant Professor, Lund University
- 4.40 Chairman's Closing Remarks and Close of Day Two



# our registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711

#### HALF-DAY POST-CONFERENCE WORKSHOP

Thursday 13th November 2014 | 8.30am – 12.30pm Marriott Regents Park Hotel, London

#### Clinical Trials in CNS: The role of academic institutions as CROs

#### **Overview of workshop:**

The aim of the workshop is to identify the common issues that arise during a clinical trial and to provide the necessary solutions for a successful partnership amongst all stakeholders.

Why you should attend:

- To enhance your understanding of regulations and documentations as well as the differences between the EMA & FDA approach
- To gain an in depth understanding of the importance of data management and quality control in Clinical Trials
- To understand the key responsibilities and procedures of all partners involved

Programme:

#### 8.30 **Registration and coffee**

#### 09.00 Opening Remarks

- 09.10 I Introduction of new lab methods into clinical use
  - Validation, recognize and transfer
    - clinical relevance
  - Security for patients and CRO/ Lab Insurances, authorship
- 09.40 II Regulations and Documentation

  - Differences EMA/FDA Responsibilities Hospital, CRO
  - Selection of patients/precipitants Form of Documentation
  - Controlling procedures and participants
- 10.10 III Quality control Methods are feasible for control, new
  - development of control methods Clinical Trail units/regular Audits
  - Topics which have to be covered
- 10.40 Morning coffee
- 11.10 IV Data Management
  - Clinical centres which have to be
  - involved
  - Anonymisation
  - Storage for clinical and study reasons Data Tranfer
- 11.40 V Cooperation
  - Selection of collaborators (students, Doctors)
  - Trained, untrained, specialized
    Communication of progress and
  - drawbacks
  - Solving difficult situations
- 12.15 Closing Remarks and wrap up

#### 12.30 End of Workshop

#### About the workshop host:



Ernst-Wilhelm Radue is CEO of the MIAC, an affiliated company of the University Hospital Basel. He received his undergraduate training at the

Universities of Erlangen, Duesseldorf and Zurich, and obtained his medical degree from the University Hospital in Freiburg, Germany, where he also specialised in Neurology and Psychiatry in 1979. He deepened his studies in Neuroradiology at the Lysholm Department of the Hospital for Nervous Diseases in London and went on to Specialize in Radiology, Neuroradiology and Neurology in Basel, Switzerland, in 1984. In 1993 he was appointed Professor of Neuroradiology. From 1984-2009 he was Head of the Department of Neuroradiology at the University Hospital Basel. Upon retirement in 2009 he is CEO of the MIAC.

His main research interests have been multiple sclerosis, cerebrovascular diseases, brain tumours and functional MRI. In 1995, he founded the MIAC in Basel, thus focussing his research ambitions on multiple sclerosis. Since then, the Medical Image Analysis Center has carried out under his responsibility several international multicentre studies, mainly in MS.

#### SMI'S PHARMACEUTICAL PORTFOLIO 2014

#### **SEPTEMBER**

Cancer Vaccines 15 - 16 September 2014, London

**Biosimilars and Biobetters** 29 - 30 September 2014, London

#### **OCTOBER**

European Pharmaceutical Pricing and Reimbursement 13 - 14 October 2014, London

Orphan Drugs 20 - 21 October 2014, London

COPD: Novel Therapeutics and Management Strategies 20 - 21 October 2014, London

Point of Care 27 - 28 October 2014, London

#### **NOVEMBER**

Cell Based Assays 19 - 20 November 2014, London

Clinical Trials in CNS 11 - 12 November 2014, London

#### DECEMBER

Cold Chain Distribution 2 - 3 December 2014, London

#### SPONSORSHIP AND EXHIBITION OPPORTUNITIES

SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company's marketing strategy.

Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call:

Alia Malick, Director on+44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk

# **CLINICAL TRIALS IN CNS 2014**

Conference: Tuesday 11th and Wednesday 12th November 2014, Marriott Regents Park Hotel, London I Workshop: Thursday 13th November 2014, London

### — 4 WAYS TO REGISTER -

#### ONLINE www.clinicaltrialscns.com

FAX your booking form to +44 (0) 870 9090 712 PHONE on +44 (0) 870 9090 711 **POST** your booking form to: Events Team, SMi Group Ltd, 2nd Floor South, Harling House, 47-51 Great Suffolk Street, London, SE1 OBS, UK

		EARLY BIRD       Book by 18th July to receive £300 off the conference price         DISCOUNT       Book by 30th September to receive £100 off the conference price					
		CONFERE	ENCE PRIC	ES GRO	UP DISCO	UNTS A	VAILABLE
Unique Reference Number		I would like to	attend: (Please	tick as appropriate)	Fee		Total
Our Reference	P-123	Conferenc	ce & 1 Workshop	p	£2098.00	+ VAT	£2517.60
DELEGATE DETAILS		Conferenc	ce only		£1499.00	+ VAT	£1798.80
		1 Workshop	p only		£599.00	+ VAT	£718.80
	l letters. Please photocopy for additional delegates.	PROMOTIONA		STRIBUTION			
Title: Forename:				any's promotional			
Surname:		literature to	o all conference	e attendees	£999.00	+ VAT	£1198.80
Job Title:		The conference			f		
Department/Division:				eshments, lunch, con ons that are available			
Company/Organisation:		distribution rights by speakers. Please note that some presentations may not be available for download. Access information for the document portal will be sent to the e-mail address provided during registration. Details are sent within 24 hours post					
Email:							
Company VAT Number:		conference.					J
Address:							
		LIVE STRE	AMING/O	N DEMAND/	DOCU/	MENT/	ATION
Town/City:		Unable to travel, but would like to watch the conference live,					
Post/Zip Code: Country:		ask questions	, participate as	if you were in the			
Direct Tel:	Direct Fax:				Price		Total
Mobile:		Live Stream	0		£999.00 £599.00		£1198.80 £718.80
Switchboard:			24 hours after t	the event)	1377.00	TVAI	1710.00
Signature: Date:				e documentation			
I agree to be bound by SMi's Terms and Conditions of Booking.  ACCOUNTS DEPT			cument Portal	ations – paper cop	£499.00	+ VAI -	£598.80 £499.00
Title: Forename:				the Document Porta		-	1477.00
Surname:							
Email:		PAYMEN1	Т				
Address (if different from above):							
Address (il dillereni noni above).				Group Ltd, and receiv reference P-123 and			
		made within 7 d	days of the event	t require payment or			
Town/City:			ase indicate meth	. ,			
Post/Zip Code:	Country:	UK BACS		<b>00009,</b> Account <b>0093</b> ank plc, 39 Threadne		london I	
	Direct Fax:		Swift (BIC): L IBAN <b>GB48</b> L	OYDGB21013, Accou OYD 3000 0900 9364	unt 00936418 18	3	
VLINUL Marriott Regents Park H	lotel, 128 King Henry's Road, London, NW3 3ST	Cheque		y accept Sterling che ∕lasterCard □ Amer			bank.
Please contact me to bo				ubject to standard credi			
Alternatively call us on +44 (0) 8 email: hotels@smi-online.co.uk (							
Terms and Conditi		Card No:		Expiry Date			
	ne of booking, then an invoice will be issued and must						
be paid immediately and prior to the start ( credit card details will be requested and pay 7 days of event require payment on booking	of the event. If payment has not been received then yment taken before entry to the event. Bookings within g. Access to the Document Portal will not be given until	CVV Number		3 digit security on reverse	e of card, 4 dig	gits for AM	EX card
payment has been received. Substitutions/Name Changes: If you are und	able to attend you may nominate, in writing, another		unite.				
delegate to take your place at any time prior to the start of the event. Two or more delegates may not 'share' a place at an event. Please make separate bookings for each delegate.		Signature: Date:					
Cancellation: If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing		-	by SMi's Terms and Conc	-			
that cancellation is made in writing and rec Regretfully cancellation after this time ca conferences documentation via the Docum to attend for any reason. Due to the interac provide documentation in these circumstant for Documentation or the Document Portal c	ceived at least 28 days prior to the start of the event, annot be accepted. We will however provide the nent Portal to any delegate who has paid but is unable tive nature of the Briefings we are not normally able to ces. We cannot accept cancellations of orders placed as these are reproduced specifically to order. If we have e will make a full refund immediately, but disclaim any	Card Billing Add	dress (If different )	from above):			
	s to make alterations to the content, speakers, timing,	$\Box$					
Data Protection: The SMi Group gathers pers	sonal data in accordance with the UK Data Protection	VAT					
products and services. Unless you tick here complementary products or services. If you that we hold then please contact our Datab	J by telephone, fax, post or email to tell you about other Jwe may also share your data with hind parties offering have any queries or want to update any of the data sace Manager databasemanager@minolnie.co.uk or tes quoting the URN as detailed above your address on	VAT at 20% is charge Streaming, on Den	mand, Document po	ince fees for all delegate ortal and literature distrib ion number for their own	ution for all UK		

If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk